NEWS & EVENTS

Catalent, today announced that professor David Schaffer has been appointed to the advisory board of the company’s biologics business.

Catalent today announced that Alex Haig, Senior Director, Engineering will present at the Pharma Forum, to be held at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18 – 19, 2019.

Catalent today announced it is to invest $9 million in a new clinical supply facility in San Diego, due to open in the summer of 2020.

Catalent today announced that Rob Harris, Ph.D., Director, Science & Technology will present at the upcoming Nordic Life Science Days (NLS Days) conference, being held at the MalmöMässan Exhibition & Congress Center, Malmö, Sweden on Sept. 10 – 12, 2019.

Catalent today announced that Steve Hager, Ph.D., Senior Director, Technical Support will present at the BioProcess International (BPI) East Conference, to be held at the Boston Convention and Exhibition Center, Boston, on Sept. 9 – 12, 2019

Catalent, today announced that Rob Harris, Ph.D., Director, Science & Technology has been invited to present at the upcoming 6th Prague-Weizmann “Advances in Drug Discovery” Summer School, to be held at Masaryk College, Prague, Czech Republic on Sept. 2 – 6, 2019.

Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit today announced the closing of their previously announced arrangement.

Catalent today announced it has appointed Ricardo Pravda as Senior Vice President and Chief Human Resources (HR) Officer. Mr. Pravda reports to John Chiminski, Catalent’s Chair and CEO, joining the company’s executive leadership team.

Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).